AOU di Modena
Modena, 41124, Italy
NCT Number: NCT06980792
The study focuses on patients with synchronous liver metastasis from pancreatic adenocarcinoma that underwent both pancreatic and liver resection. The control group is made up of patients with resectable or borderline resectable pancreatic adenocarcinoma and synchronous liver metastasis that were excluded from surgery. Short and long-term outcomes will be compared to evaluate the safety and efficacy of simultaneous liver and pancreatic resection.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Modena, 41124, Italy
The study focuses on patients with synchronous liver metastasis from pancreatic adenocarcinoma that underwent both pancreatic and liver resection. The control group is made up of patients with resectable or borderline resectable pancreatic adenocarcinoma and synchronous liver metastasis that were excluded from surgery. Short and long-term outcomes will be compared to evaluate the safety and efficacy of simultaneous liver and pancreatic resection.
However, historical results regarding hepatic resection for PDAC were in conflicts and remained controversial. Furthermore, rare systematic review or meta-analysis was ever reported focusing on PDAC as a separate group. A recent meta-analysis reported that overall survival of PDAC patients can benefit from hepatic resection to some extent. It has been also recently showed that that surgical resection of pancreatic cancer with synchronous liver oligometastases is safe, and it can be associated with improved survival, providing a careful selection of patients after primary chemotherapy. Since a randomized controlled trial may be ethically questionable, a multicenter international retrospective study may clarify the role of liver resection in this cohort of patients.
2.2 Objectives
The primary aim is to examine recurrence free survival (RFS) and overall survival (OS) following surgical resection of synchronous hepatic metastases from PDAC, and to study the role of tumor burden and chemotherapy regimen on survival.
3.1 Study design Patients underwent liver resection for synchronous metastases from pancreatic adenocarcinoma, single or multiple metastasis, will be included in the study, without any time interval limitation.
Clinical features, operative data and chemotherapy regimens will be analyzed. A control group of non-surgical patients will be included in the study for a propensity score match.
3.2 Setting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Surgery for synchronous liver metastasis from PDAC with or without previous neoadjuvant chemotherapy
Chemotherapy alone in potentially resectable patients with PDAC and synchronous liver metastasis
Time frame: 3 years
Time frame: 3 years
Time frame: 90 days
comprehensive complication index (using the online official CCI calculator that combines the events based on the Clavien-Dindo Classification)
Time frame: up to 100 weeks
ICU and in-hospital stay (days)
Time frame: up to 100 weeks
surgical margin (in millimeters) and R status (R 0: no infiltration; R 1: microscopic infiltration; R 2: macroscopic infiltration) of pancreatic and hepatic specimens; nodal status (number of nodes sampled and number of positive nodes)
Azienda Ospedaliero-Universitaria di Modena
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00377936
Adenocarcinoma, Carcinoma
Prague, Czechia
View Trial DetailsNCT02905578
Adenocarcinoma, Cancer of Pancreas
Iowa City, Iowa, United States
View Trial DetailsNCT06947395
Cancer of the Pancreas, Digestive System Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT02681796
Cancer of Pancreas, Cancer of the Pancreas
St Louis, Missouri, United States
View Trial Details